Belgian Health Care REITs Stock News

DEME Group (ENXTBR:DEME) has drawn fresh attention after reporting full year 2025 results and declaring an annual dividend of €3.15 per share, with payment scheduled for May 29, 2026. See our latest analysis for DEME Group. The full year 2025 earnings update and higher dividend seem to have kept interest in the stock firm, with a 30 day share price return of 9.83% and a 90 day share price return of 26.81%. The 1 year total shareholder return of 37.96% and 3 year total shareholder return of...

Recent share performance and business snapshot Umicore (ENXTBR:UMI) has drawn investor attention after recent share price pressure, with the stock showing a 5.4% decline over the past day and a 15.1% decline over the past month. Over the past 3 months, the shares show a 9.4% total return, while the past year reflects a 108.4% total return. Over a longer horizon, 3 year and 5 year total returns are negative at 41.1% and 60.3% respectively. The company reports revenue of €19.4b and net income...

Earnings and dividend proposal draw attention to VGP (ENXTBR:VGP) VGP (ENXTBR:VGP) has come onto investors' radar after reporting full year 2025 results alongside a proposed 3% increase in its ordinary dividend to €3.40 per share. See our latest analysis for VGP. Despite a 1-day share price decline of 5.84% to €100.0 and softer 7-day and 30-day share price returns, VGP’s 1-year total shareholder return of 33.21% and 3-year total shareholder return of 26.54% point to momentum that has largely...

In February 2026, UCB SA reported full-year 2025 results showing sales of €7,388 million and revenue of €7,741 million, with net income rising to €1.56 billion and basic earnings per share from continuing operations of €8.20. Alongside this earnings improvement, UCB secured FDA approval for KYGEVVI, the first treatment for ultra-rare TK2 deficiency, and committed US$5 billion to a new US mammalian manufacturing site, reinforcing its focus on complex biologics and rare diseases. Next, we’ll...

If you are wondering whether NV Bekaert at €43.00 is genuinely good value or just looks that way on the surface, you are in the right place. Over the past year the share price has returned 29.0%, with a 3.6% gain over 30 days, even though the last 7 days saw a 1.8% decline, which can change how investors think about both upside and risk. Recent coverage of NV Bekaert has focused on the company as a long established materials player, with attention on how it is positioning itself within its...

If you are wondering whether Syensqo's current share price reflects its underlying worth, you are not alone; many investors are asking the same question right now. The stock last closed at €49.00, after declines of 36.9% over 7 days, 31.0% over 30 days, 29.9% year to date and 28.8% over the past year, which can change how the market views both its potential and its risks. Recent news coverage has focused on Syensqo as part of ongoing evergreen interest in the stock, with attention on how its...

Cmb.Tech (ENXTBR:CMBT) is back in focus after reporting fourth quarter and full year 2025 results. The company highlighted higher sales, solid profits, lower debt, and an interim dividend that puts cash returns on the table. See our latest analysis for Cmb.Tech. The latest earnings, dividend announcement and management board change have arrived alongside strong momentum, with a 30 day share price return of 14.44% and a 1 year total shareholder return of 41.69%, suggesting sentiment has been...

Proximus (ENXTBR:PROX) is back in focus after its full year 2025 earnings showed lower net income, alongside announced job reductions and a dividend cut. These moves coincided with sharp share price volatility. See our latest analysis for Proximus. The sharply negative 1 day share price return of 15.94% following the earnings release and restructuring news has erased recent gains, even though the 1 year total shareholder return is 20.86% and the 5 year total shareholder return is 38.77%...

Argenx (ENXTBR:ARGX) reported positive topline Phase 3 ADAPT OCULUS results for VYVGART in adults with ocular myasthenia gravis. The study met its primary endpoint with statistically significant efficacy in this patient group, which currently has limited treatment options. The data are intended to support regulatory submissions that could extend the existing VYVGART label to include ocular myasthenia gravis. Argenx is pairing these results with a broader push to expand VYVGART indications...

UCB (ENXTBR:UCB) has kicked off FY 2025 with first half revenue of €3.5b and basic EPS of €2.50, following a FY 2024 second half that delivered €3.4b in revenue and basic EPS of €4.51. The company has reported an increase in revenue from €2.8b and basic EPS of €1.10 in the first half of 2024 to the latest €3.5b and €2.50, with trailing 12 month basic EPS of €8.20 on revenue of €7.7b. For investors, that mix of higher recent earnings, stronger trailing profitability and a 20.1% net margin...

Cofinimmo (ENXTBR:COFB) has released its fourth quarter and full year 2025 results, reporting sales of €93.56 million and net income of €43.27 million for the quarter, highlighting its improved profitability. See our latest analysis for Cofinimmo. The recent earnings release comes after a strong run in the shares, with the 90 day share price return of 18.69% and year to date share price return of 15.66% adding to a 1 year total shareholder return of 66.31%. In contrast, the 5 year total...

Proximus FY 2025 results put margins and one offs in focus Proximus (ENXTBR:PROX) has wrapped up FY 2025 with fourth quarter revenue of €1.9b and net income of roughly €0m, capping a year in which trailing twelve month revenue came in at €6.6b and net income at €398m. Over recent periods the group has seen quarterly revenue move from €1.67b in Q4 2024 to €1.93b in Q4 2025. EPS across 2025 ranged from €0.26 to €0.54 per quarter, setting the backdrop for a year where earnings were also shaped...

UCB (ENXTBR:UCB) drew investor attention after its 2025 earnings, reporting revenue of €7.74b, net income of €1.56b, and basic earnings per share from continuing operations of €8.20. See our latest analysis for UCB. The share price reaction has been mixed in the short term, with a 1 day share price return of 1.57% after results set against a 7 day share price return of an 8.62% decline. The 1 year total shareholder return of 39.89% and 5 year total shareholder return of 240.37% point to...

argenx (ENXTBR:ARGX) has wrapped up FY 2025 with Q4 revenue of US$1.3b and basic EPS of US$8.63, rounding out a year in which trailing twelve month revenue reached US$4.2b and EPS came in at US$21.08. The company has seen quarterly revenue move from US$757.39m in Q4 2024 to US$1.3b in Q4 2025, while quarterly EPS shifted from US$12.79 to US$8.63 over the same period, setting the stage for trailing twelve month earnings of US$1.29b. With earnings growth over the last year and a reported net...

Azelis Group (ENXTBR:AZE) shares are in focus after the company reported full year 2025 results showing lower sales and net income, alongside a proposed €0.226 per share dividend with a late June ex dividend date. See our latest analysis for Azelis Group. The full year 2025 results and lower proposed dividend come after a year where Azelis Group’s share price return slipped, with a year to date share price return of 10.12% and a 1 year total shareholder return decline of 53.49%, hinting that...

Aedifica/SA (ENXTBR:AED) just released its full year 2025 results, reporting €360.95 million in sales, €244.43 million in net income and confirming a proposed €4.00 per share gross dividend for May 2026. See our latest analysis for Aedifica/SA. The latest figures and confirmed €4.00 dividend proposal come after a period of strong momentum, with a 90 day share price return of 18.27% and a 1 year total shareholder return of 32.20% from a €78.65 share price starting point. If this earnings...

Interest in Syensqo (ENXTBR:SYENS) has picked up after the company reported 4% full year net sales growth in Composite Materials and exited its Oil & Gas unit, sharpening its focus as a pure play specialty company. See our latest analysis for Syensqo. That sharper focus has not yet shown up in the price, with the share price at €48.37 and recent momentum clearly weak, including a 7 day share price return of 37.94% decline and a 1 year total shareholder return of 30.03% decline. If Syensqo’s...

How Anheuser-Busch InBev’s Recent Performance Is Catching Investor Attention Anheuser-Busch InBev (ENXTBR:ABI) has drawn fresh interest after a recent run of positive returns, with the share price showing gains over the past week, month, past 3 months, and year to date. See our latest analysis for Anheuser-Busch InBev. That recent momentum, with a 30 day share price return of 17.20% and 90 day share price return of 29.80% taking the share price to €68.82, sits alongside a 1 year total...

Cmb.Tech (ENXTBR:CMBT) has just posted its FY 2025 numbers, with fourth quarter revenue of US$590.5 million and basic EPS of US$0.31, while trailing 12 month revenue came in at about US$1.9 billion alongside basic EPS of US$0.70. Over recent periods, the company has seen revenue move from US$226.0 million and basic EPS of US$0.48 in Q4 2024 to US$590.5 million and US$0.31 in Q4 2025. This gives investors a clear set of markers to track how the earnings story is evolving. With trailing net...

ageas (ENXTBR:AGS) is back in focus after proposing a total gross cash dividend of €3.75 per share for 2025, a 7% increase compared with 2024, following a year of significant corporate changes. See our latest analysis for ageas. The proposed higher dividend comes after a period where momentum in ageas shares has been building, with a 30-day share price return of 9.0% and a 1-year total shareholder return of 24.32% supported by its transformational deals and repositioning in core insurance...

If you are wondering whether argenx is still worth your attention at current prices, a key question is how its market value compares with its fundamentals. The share price last closed at €652.00, with returns of 6.6% over 1 year, 100.3% over 3 years, and 157.7% over 5 years. More recently, it has seen a 9.1% decline over 7 days, 11.0% over 30 days, and 9.9% year to date. Recent news around argenx has focused on its position in the pharmaceuticals and biotech space and investor interest in...

Solvay (ENXTBR:SOLB) has wrapped up FY 2025 with fourth quarter revenue of €1.1b and a basic EPS loss of €0.90, capping a year in which trailing twelve month EPS came in at €0.29 on revenue of €4.7b. Over the past few quarters, the company has seen quarterly revenue move from €1.24b in Q1 2025 to €1.09b in Q4 2025, while basic EPS ranged from €0.78 in Q1 to a loss of €0.90 in Q4. This presents a picture where thin margins and that final quarter loss sit alongside expectations for stronger...

Event context and recent share performance With no single headline event driving attention today, NV Bekaert (ENXTBR:BEKB) is attracting interest as investors reassess the stock after a month and past 3 months of double digit total returns. See our latest analysis for NV Bekaert. The recent 9.95% 1 month share price return and 20.60% 3 month share price return, alongside a 34.09% 1 year total shareholder return, point to building momentum as investors reassess NV Bekaert at around €44.2 per...

Recent performance snapshot argenx (ENXTBR:ARGX) has seen mixed share performance recently, with a small move over the past week, a modest gain over the past month, and a double digit decline across the past 3 months. Over a longer horizon, argenx shows a positive year to date return and a higher 1 year total return, while the 3 year and 5 year total returns are considerably above its shorter term moves. See our latest analysis for argenx. At a share price of €710.2, argenx’s recent 10.19% 3...